Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.37 |
| ▸ | IDH2 | P48735 | 4/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15749038 | 1.00 | IDH1 (0.37) | IDH1IDH2ABL1LATS1LATS2 | |
| SCHEMBL15740528 | 1.00 | IDH1 (0.37) | IDH1IDH2ABL1LATS1LATS2 | |
| SCHEMBL15740748 | 0.88 | IDH1 (0.37) | IDH1IDH2ABL1LATS1LATS2 | |
| SCHEMBL17447755 | 0.83 | IDH1 (0.38) | IDH1IDH2ABL1LATS1LATS2 | |
| SCHEMBL15740568 | 0.82 | KAT2B (0.37) | — | |
| SCHEMBL15741015 | 0.81 | ABL1 (0.32) | IDH1IDH2ABL1 | |
| SCHEMBL19015419 | 0.78 | IDH1 (0.35) | IDH1IDH2ABL1 | |
| SCHEMBL15749026 | 0.76 | TDP1 (0.36) | LATS1LATS2 | |
| SCHEMBL15740596 | 0.76 | ALDH1A1 (0.36) | IDH1IDH2 | |
| SCHEMBL15740626 | 0.76 | ALDH1A1 (0.36) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | IDH1 829/4885IDH2 1311/4885ABL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.